E-ISSN: 2148-5402 | Contact
Prognostic and clinical impact of pleural effusion in lung cancer patients
1Baku Medical Plaza, Baku, Azerbaijan
2Department of Pulmonary Medicine, Eskişehir Osmangazi University, Faculty of Medicine, Eskişehir, Türkiye; Lung and Pleural Cancers Research and Clinical Center, Eskişehir Osmangazi University, Eskişehir, Türkiye
3Lung and Pleural Cancers Research and Clinical Center, Eskişehir Osmangazi University, Eskişehir, Türkiye
Eurasian Journal of Pulmonology - DOI: 10.14744/ejp.2026.19958

Abstract

BACKGROUND AND AIMS: The aim of this study was to evaluate the frequency, causes, predictors, and prognostic impact of pleural effusions detected at diagnosis and during follow-up in lung cancer patients in a tertiary care hospital.

MATERIALS AND METHODS: In 895 lung cancer patients, pleural effusions identified at diagnosis or follow-up were classified as malignant, benign, or undetermined. Predictors for pleural effusion were evaluated by univariate logistic regression, and survival was analyzed using Kaplan-Meier and Cox regression models.

RESULTS: The mean age was 63.6±9.5 years (range: 35–87), and 89.2% were male. Pleural effusion occurred in 32.1% at diagnosis and 22.8% during follow-up. Malignant pleural effusion (MPE) predominated at diagnosis (47.7%), whereas benign pleural effusion (BPE) was more frequent during follow-up (33.8%, p<0.001). At diagnosis, pleural effusion risk was higher in patients ≥65 years, females, never-smokers, those with central/lower lobe tumors, and Eastern Cooperative Oncology Group (ECOG) ≥1; during follow-up, it was associated with central lesions, and stage III–IV disease (all p<0.05). The shortest overall survival was observed in patients with MPE at diagnosis (5.0±0.92 months), and the longest in those with BPE during follow-up (21.0±2.19 months) (log-rank: 83.029; p<0.001). Hazard ratios were higher in small cell versus squamous (p<0.001), ECOG ≥1 versus 0 (p=0.001), untreated patients (p<0.001), and those with MPE at diagnosis (p=0.027).

CONCLUSION: Pleural effusion remains a frequent and clinically relevant challenge in patients with lung cancer, both at diagnosis and during follow-up. Accurate identification of its etiology is essential to guide appropriate management and estimate prognosis.